KRAS and pancreatic ductal adenocarcinoma: Collectively, the data highlights the promising anticancer potential of these novel derivatives, targeting PDK, towards obtaining clinical candidates for combatting highly aggressive KRAS-mutant pancreatic ductal adenocarcinoma.